Danish biotech Genmab (CPH: GMAB) today announced it has named Leslie Amendola senior vice president and general manager of its US business.
In this role, Ms Amendola will lead US operations, driving forward Genmab’s commitment to transforming the lives of people impacted by cancer or other serious diseases.
Bringing a track record of extensive leadership and successful commercialization experience, Ms Amendola joined Genmab in 2021 as the US VP of sales and marketing, where she led two major drug launches.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze